Pfizer is expanding its R&D efforts in China and announced plans to create a replacement facility.
An agreement has been signed to determine a replacement Pfizer R&D centre in Wuhan, which the firm says represents an expansion of its existing facility in Shanghai. Once the new plant is made , the corporate expects the amount of employees to grow to 200 within three years but gave no details about the financial investment involved.
Pfizer noted that its Wuhan operation will liaise with local research institutes and universities “utilising the rich resources of local talent and existing industry capabilities to develop research collaborations”. It stressed that Shanghai will remain “the operations hub of Pfizer’s R&D effort in China”.
Allan Gabor, the company’s North Asia president, noted that it’s the primary to determine a big R&D presence in China’s Central/Western region. He added that the Wuhan centre are going to be an integral a part of Pfizer’s global R&D operations “while being closely aligned with the Chinese government’s strategy on biopharmaceutical industry development within the region.”
The site are going to be based at the Wuhan National Bioindustry Base, or Biolake, the development that started in November last year.